These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9804127)

  • 21. Cytochromes and psychotropic drug interactions.
    Bates GD; Van Woerkom AE
    Br J Psychiatry; 1996 Nov; 169(5):670. PubMed ID: 8932910
    [No Abstract]   [Full Text] [Related]  

  • 22. [CYP2D6 gene polymorphism in psychiatric patients resistant to standard pharmacotherapy].
    Zabrocka M; Woszczek G; Borowiec M; Rabe-Jabłońska J; Kowalski ML
    Psychiatr Pol; 1999; 33(1):91-100. PubMed ID: 10786218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].
    Reggiani K; Vandel P; Haffen E; Sechter D; Bizouard P; Vandel S
    Encephale; 2000; 26(1):62-7. PubMed ID: 10875063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical pharmacogenetics in the treatment of schizophrenia].
    Saito M; Yasui-Furukori N; Kaneko S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome.
    Ram A; Cao Q; Keck PE; Pope HG; Otani K; Addonizio G; McElroy SL; Kaneko S; Redlichova M; Gershon ES
    Am J Med Genet; 1995 Jun; 60(3):228-30. PubMed ID: 7573176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parkinson's disease, CYP2D6 polymorphism, and age.
    Payami H; Lee N; Zareparsi S; Gonzales McNeal M; Camicioli R; Bird TD; Sexton G; Gancher S; Kaye J; Calhoun D; Swanson PD; Nutt J
    Neurology; 2001 May; 56(10):1363-70. PubMed ID: 11376189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No association between the neuroleptic malignant syndrome and mutations in the RYR1 gene associated malignant hyperthermia.
    Miyatake R; Iwahashi K; Matsushita M; Nakamura K; Suwaki H
    J Neurol Sci; 1996 Nov; 143(1-2):161-5. PubMed ID: 8981316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.
    Hendset M; Molden E; Knape M; Hermann M
    Ther Drug Monit; 2014 Feb; 36(1):80-5. PubMed ID: 24232129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients.
    Ieiri I; Yamada S; Seto K; Morita T; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
    Pharmacopsychiatry; 2003 Sep; 36(5):192-6. PubMed ID: 14571354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient.
    Bottlender R; Jäger M; Hofschuster E; Dobmeier P; Möller HJ
    Pharmacopsychiatry; 2002 May; 35(3):119-21. PubMed ID: 12107858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.
    Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T
    Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes.
    Senda C; Yamaura Y; Kobayashi K; Fujii H; Minami H; Sasaki Y; Igarashi T; Chiba K
    Br J Clin Pharmacol; 2001 Jul; 52(1):100-3. PubMed ID: 11453897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.
    Kirchheiner J; Nickchen K; Bauer M; Wong ML; Licinio J; Roots I; Brockmöller J
    Mol Psychiatry; 2004 May; 9(5):442-73. PubMed ID: 15037866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacogenetics or "farm-ecogenetics"?].
    Gérard N; Elion J; Krishnamoorthy R
    J Soc Biol; 2000; 194(1):9-13. PubMed ID: 11107543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
    Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
    Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Case report: Neuroleptic malignant syndrome and diagnostic difficulties].
    Khouri C; Planès S; Logerot S; Villier C; Mallaret M
    Encephale; 2016 Jun; 42(3):277-80. PubMed ID: 26923996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is pharmacogenetic CYP2D6 testing useful?
    Vetti HH; Molven A; Eliassen AK; Steen VM
    Tidsskr Nor Laegeforen; 2010 Nov; 130(22):2224-8. PubMed ID: 21109842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic polymorphism of CYP2D6 in the Japanese population.
    Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez FJ; Kamataki T
    Pharmacogenetics; 1999 Oct; 9(5):601-5. PubMed ID: 10591540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No evidence of an association between CYP2D6 polymorphisms among Japanese and dementia with Lewy bodies.
    Furuno T; Kawanishi C; Iseki E; Onishi H; Sugiyama N; Suzuki K; Kosaka K
    Psychiatry Clin Neurosci; 2001 Apr; 55(2):89-92. PubMed ID: 11285084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.